Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: David S. who wrote (3662)	1/25/1998 4:56:00 PM
From: JOHN W.	Read Replies (1) \| Respond to of 6136

Yeah I remember you suggesting AIDS patients try chicken soup. Your brand of B.S. has the lifespan of a Hong Kong chicken, put that in your soup. PW (1/23/98) cont: "Sizeable market opportunity. We estimate that there are approx 400,000 HIV infected patients in Europe representing a sizable market.. We expect the pricing for the product will be similiar to the U.S. AGPH will receive royalties on product sales (we estimate 10-14%) that step-up with increasing sales. Agouron also recognizes manufacturing revenues from supplying Viracept to Roche." cont....

To: David S. who wrote (3662)	1/25/1998 5:21:00 PM
From: JOHN W.	Read Replies (2) \| Respond to of 6136

Chicken Soup and serious diseases. "Approval in Japan imminent; Roche strikes co-promotion deal with Japan Tobaccofor Japan market. In addition, Japan Tobacco announced a co-promotion ageement with Roche to sell Viracept in Japan. Last July, Roche obtained exclusive marketing rights to Viracept in several other Asian terriotopries including China, India, Turkey, the Phillipines, Singapore, Taiwan, Thailand, and Vietnam . Japan Tobacco filed for marketing approval of Viracept i8n Japan in May 1997. We expect approval in Japan will occur this quarter. Although Japan is a substantially smaller market than the U.S and Europe, approval would be yet another milestone for the company and will potentially pave the way to approval in other Asian countries representing larger markets."